Enhanced recovery mitigates sodium-glucose cotransporter-2 inhibitors associated mobility decline in valve surgery patients

SGLT2i use is associated with transient perioperative mobility impairment in VHD patients, evidenced by longer ICU stays and delayed mobilization. However, a structured ERAS protocol effectively mitigates these limitations, facilitating superior functional recovery by discharge. These findings underscore the necessity of adapting or closely monitoring ERAS protocols, particularly for patients on SGLT2i, to mitigate early mobility deficits. This supports tailoring ERAS pathways, particularly early mobilization, for this patient population.